PDUFA Trading Strategies
How to Trade Around FDA Decision Dates

1. The Pre-PDUFA Run-Up: Trading the Anticipation
2. Historical PDUFA Outcomes: Approval vs CRL Data
3. AdCom Votes as Predictors
4. Understanding IV Crush: The Options Trap
5. Options Strategies for PDUFA Dates
6. Position Sizing for Binary Events
7. Sell the News: Post-Approval Trading Patterns
8. The Sell-Before Strategy: Capturing Run-Up Without Binary Risk
9. Common Mistakes in PDUFA Trading
10. FAQ

The Pre-PDUFA Run-Up: Trading the Anticipation

One of the most consistent patterns in biotech is the pre-PDUFA run-up: the tendency for stocks to appreciate in the 2-4 weeks before a PDUFA date as traders position for the binary event. This pattern exists because:

• Traders who believe in approval buy shares to position ahead of the catalyst
• Short sellers begin covering to avoid unlimited upside risk on an approval
• Options market makers buy shares to hedge against increasing call option activity
• Media coverage increases as the PDUFA date approaches, drawing in retail attention

Historical data on pre-PDUFA performance (based on analysis of 500+ PDUFA events):

The pre-PDUFA run-up is most pronounced for small-cap biotechs ($200M-$2B market cap) with high consensus approval probability. Large-cap stocks and drugs with uncertain data packages show weaker run-ups. Track upcoming PDUFA dates on the BiotechSigns Calendar.

Historical PDUFA Outcomes: Approval vs CRL Data

Understanding the base rate of PDUFA outcomes is essential for calibrating expectations:

The overall NDA/BLA approval rate of approximately 85-90% at the PDUFA stage seems high, but this is survivorship bias at work. Only the strongest drug candidates survive Phase 1-3 to reach PDUFA. The cumulative probability from Phase 1 to approval is only ~7.9%. The stocks that reach PDUFA have already passed through the most severe filters.

Typical stock price reactions by outcome:

AdCom Votes as Predictors

Not all PDUFA events are equal. When the FDA convenes an Advisory Committee (AdCom) meeting before the PDUFA date (typically 1-3 months prior), the vote provides valuable predictive data:

• Strong positive vote (e.g., 12-0, 10-2): FDA follows with approval ~90-95% of the time. Stock typically appreciates 15-40% on the AdCom vote itself, then has a smaller move on the actual PDUFA date.
• Mixed vote (e.g., 7-5, 8-4): Approval probability ~65-75%. Significant uncertainty remains. The stock may have limited movement on the AdCom vote and a larger move on the PDUFA date.
• Negative vote (e.g., 4-8, 3-10): FDA issues CRL ~70-75% of the time. Stock typically drops 30-50% on the AdCom vote. A negative AdCom followed by an actual approval is rare but generates enormous upside.

Critically, not all PDUFA decisions are preceded by an AdCom meeting. The FDA decides on a case-by-case basis whether to convene an advisory committee. When no AdCom is held, it can signal either that the FDA has high confidence in the data (bullish) or that the issues are primarily manufacturing/labeling-related rather than efficacy/safety (neutral). Track AdCom schedules on the BiotechSigns Calendar.

Understanding IV Crush: The Options Trap

Implied volatility (IV) crush is the most common reason traders lose money on PDUFA options trades, even when they correctly predict the direction. Here is why:

Before a PDUFA date, options implied volatility spikes dramatically as the market prices in the potential for a large move. IV for at-the-money options may reach 200-400%+ in the week before a PDUFA date (compared to a normal IV of 60-80% for a typical biotech stock).

After the PDUFA decision is announced, the uncertainty is resolved and IV collapses — often by 50-80% overnight. This collapse in IV reduces the value of all options (both calls and puts), regardless of which direction the stock moves.

This is why buying outright calls or puts before a PDUFA date is a losing strategy on average. The IV premium you pay already reflects the expected move size. You only profit if the stock moves more than the market expected.

Options Strategies for PDUFA Dates

Here are options strategies that address the IV crush problem:

Bull Call Spread (Debit Spread)

Buy a call at one strike and sell a call at a higher strike. This reduces the cost of the trade by selling IV on the upper call, partially offsetting IV crush. Best for: High-conviction approval thesis where you want defined risk. Risk: Max loss is the debit paid.

Iron Condor (Credit Strategy)

Sell a call spread and a put spread simultaneously, collecting premium from both sides. Profits if the stock stays within a range or if IV crush reduces the value of all options. Best for: Situations where you believe the market is overpricing the expected move. Risk: Unlimited-like losses if the stock moves beyond your strikes (though defined by the spread width).

Long Stock + Protective Put

Buy shares and buy a put option as insurance. The put limits your downside to the strike price minus your cost basis. The stock position captures full upside on approval. Best for: Longer-term holders who want to hold through the PDUFA but protect against a CRL. Risk: The put premium is an insurance cost that you lose if the stock goes up.

Pre-Event Calendar Spread

Buy a longer-dated option and sell a shorter-dated option at the same strike. The shorter-dated option decays faster and is crushed by IV collapse, while the longer-dated option retains more value. Best for: Profiting from IV crush without taking a directional bet. Risk: Maximum loss is the debit paid. Requires the stock to stay near the strike.

Position Sizing for Binary Events

Position sizing is arguably the most important aspect of PDUFA trading. Even the best analysis can be wrong — a drug with 90% approval probability still fails 10% of the time, and a CRL can erase 60-80% of your position value overnight.

Rules of thumb used by experienced biotech traders:

• Maximum 2-5% of portfolio per PDUFA event. This means if you have a $100K portfolio, no more than $2K-$5K at risk on a single PDUFA date.
• Never hold more than 2-3 PDUFA events simultaneously. Multiple PDUFA losses can compound and cause portfolio-level damage.
• Use defined-risk strategies. Options spreads, protective puts, or small share positions rather than large levered bets.
• Calculate worst-case scenario before entering. If the stock drops 70% on a CRL, what is your dollar loss? Can you absorb it without emotional decision-making?
• Consider the asymmetry. If approval is expected (80%+ probability), the upside may be only 20-30% (already priced in) while the downside on a CRL is 60-80%. The risk-reward may not justify holding through the event.

Sell the News: Post-Approval Trading Patterns

A common pattern after PDUFA approval is the "sell the news" reaction: the stock gaps up on approval, then gives back some gains over the following 1-3 weeks. This happens because:

• Traders who bought for the PDUFA catalyst sell their positions ("sell the news")
• Short-term call holders close positions, reducing demand
• The market shifts focus from the binary event to commercial execution questions (sales force, launch timeline, competition, pricing)
• Some companies do follow-on offerings shortly after approval to fund commercial launch, creating dilution pressure

For investors with a longer time horizon, the post-approval pullback can be a buying opportunity. The drug is now approved, removing the largest risk, and the commercial launch ramp typically drives stock appreciation over the following 6-18 months as revenue materializes. Check whether the company has sufficient cash runway to fund the launch without dilution.

The Sell-Before Strategy: Capturing Run-Up Without Binary Risk

The most conservative PDUFA strategy is to buy 3-4 weeks before the PDUFA date and sell 1-3 days before the decision. This captures the pre-PDUFA run-up appreciation (historically 5-15% on average) without exposure to the binary outcome.

Advantages:

• No binary event risk — you are never holding through the decision
• No IV crush risk — you are not trading options
• Repeatable across many PDUFA events for consistent, moderate returns
• Works even when the drug is ultimately rejected (you exit before the decision)

Disadvantages:

• You miss the large upside if the drug is approved
• Not all stocks run up consistently (some sell off into the PDUFA date)
• Requires disciplined execution and timing

Common Mistakes in PDUFA Trading

1. Oversizing positions. The #1 mistake. Betting 10-20% of a portfolio on a single PDUFA event is a recipe for a portfolio-ending loss. Keep individual positions at 2-5% max.
2. Ignoring IV crush. Buying expensive options before PDUFA and being shocked when they lose value despite a correct directional call. Always check the implied move vs. the expected fundamental move.
3. Confusing high approval probability with guaranteed profit. A stock with a 90% approval probability may only move +15% on approval (it is already priced in) but drop 70% on a CRL. The expected value of holding may be negative.
4. Not checking the cash runway. Many companies do a dilutive offering immediately after approval to fund commercial launch. This can erase much of the approval gains. See cash runway guide.
5. Holding through multiple PDUFA events simultaneously. This compounds binary risk. One CRL can offset gains from multiple approvals.
6. Not doing independent research. Relying on social media sentiment or analyst consensus without reading the actual clinical data, FDA briefing documents, and AdCom transcripts.

Frequently Asked Questions